

Special Issue

Vaccination Advances for HBV, HPV, and Influenza

Message from the Guest Editor

Hepatitis B leads to chronic liver disease and cancer, causing approximately 1.1 million deaths annually. Human papillomavirus (HPV) is responsible for almost all cases of cervical cancer and other malignancies, resulting in over 300,000 deaths each year. With its seasonal and pandemic potential, influenza affects millions globally, leading to substantial morbidity and mortality. Vaccines for these diseases have shown effectiveness: HBV and HPV vaccines offer 90-100% against cancer-causing strains, and influenza vaccines reduce illness and death. High vaccination coverage prevents individual infections and promotes herd immunity. This Special Issue welcomes submissions including but not restricted to the following:

- Progress in HBV, HPV, or influenza vaccination among vulnerable subpopulations (e.g., infants, children, elderly, health care workers, etc);
- Integrated vaccination programs;
- Different vaccination strategies for HBV, HPV, or influenza across regions, particularly new vaccine technologies.

Guest Editor

Dr. Wangnan Cao

Department of Social Medicine and Health Education, School of Public Health, Peking University Health Science Center, Beijing 100191, China

Deadline for manuscript submissions

closed (31 August 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/210691

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).